Welcome to our dedicated page for Kazia Therapeuti news (Ticker: KZIA), a resource for investors and traders seeking the latest updates and insights on Kazia Therapeuti stock.
Kazia Therapeutics Limited (NASDAQ: KZIA) is an oncology-focused drug development and clinical-stage biotechnology company based in Sydney, Australia. News about Kazia typically centers on the progress of its investigational cancer therapies, particularly its lead program paxalisib, as well as pipeline additions such as EVT801 and a first-in-class PD-L1 protein degrader program.
Company announcements frequently highlight clinical and translational data for paxalisib, a brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway. Recent news has included results from glioblastoma studies, early efficacy and biomarker findings in advanced triple-negative breast cancer and HER2-positive metastatic breast cancer, and mechanistic data showing reductions in circulating tumor cells and clusters, changes in tumor cell phenotypes, and reinvigoration of immune cell function.
Kazia’s news flow also covers regulatory and development strategy updates, such as its intention to request FDA Type C meetings to discuss overall survival data in newly diagnosed glioblastoma and potential regulatory pathways, as well as participation in initiatives like an Australian Medical Research Future Fund project using AI-enabled platforms to guide therapy sequencing in diffuse midline glioma and diffuse intrinsic pontine glioma.
Investors following KZIA news will also find information on capital markets activities, including private placements of equity securities, at-the-market offerings of American Depositary Shares, and Nasdaq listing compliance developments. Updates on the EVT801 VEGFR3 inhibitor program, the NDL2 PD-L1 degrader collaboration with QIMR Berghofer, and participation in major oncology conferences provide additional context on Kazia’s evolving pipeline and scientific positioning.
This news page aggregates these disclosures so readers can track key milestones in Kazia’s clinical programs, regulatory interactions, collaborations, and financing events over time.
Kazia Therapeutics reported its Q123 cash flow, revealing a period dominated by challenges faced by paxalisib in the GBM AGILE study. Despite this setback, there was clinical progress in pediatric brain cancers and brain metastases. The company ended the quarter with a cash balance of AU$5.3m (c US$3.4m) and expects this to last until the end of CY22. R&D expenses totaled AU$4.3m, and with the completion of enrollment for the GBM study, future expenditures are projected to decrease significantly.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced new data from its collaboration with the Huntsman Cancer Institute, showing that paxalisib is effective against preclinical models of metastatic melanoma. Dr. Gennie Parkman presented data indicating that paxalisib shows promise as a monotherapy and even greater efficacy in combination with existing therapies. With melanoma affecting about 100,000 Americans annually and a high mortality rate, further clinical trials for paxalisib in this area are anticipated in the near future, aiming to address unmet medical needs.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced the international expansion of its phase II study of paxalisib, aimed at treating diffuse intrinsic pontine glioma (DIPG) and other diffuse midline gliomas (DMGs). This study, sponsored by the Pacific Pediatric Neuro-Oncology Consortium, has recently opened two sites in Australia, marking its first trial in the country. The trial combines paxalisib with ONC201 and is currently active at nine sites in the U.S. and two in Australia, with plans for further international expansion. Initial data is anticipated in 2023.
Kazia Therapeutics Limited (NASDAQ: KZIA) announced that CEO Dr. James Garner will present at the 24th Annual Global Investment Conference in New York from September 12-14, 2022. The presentation will highlight three positive data read-outs from Kazia's oncology programs in 2022 and discuss upcoming developments. The company's management team will also hold one-on-one meetings with institutional investors during the conference. Kazia is focused on developing treatments for aggressive brain cancers, including their lead program, paxalisib.
Kazia Therapeutics Limited (NASDAQ: KZIA) has announced that final data from its phase II study of paxalisib in patients with newly diagnosed glioblastoma will be presented at the European Society for Medical Oncology (ESMO) annual congress in Paris, France from September 9-13, 2022. The presentation will detail findings previously highlighted at the ASCO Annual Meeting in June 2022. Professor John de Groot from the University of California, San Francisco will deliver the presentation, covering pharmacokinetics and pharmacodynamics.
Kazia Therapeutics reported busy FY22 results focusing on its oncology pipeline. The year featured positive data from preclinical and clinical programs, especially in childhood brain cancers. However, the lead asset paxalisib did not advance to Stage 2 in the Phase III GBM AGILE study for glioblastoma multiforme. The company's net cash at year-end stood at US$5.3m, needing an estimated US$50m more to reach break-even. Valuation remains at US$146.6m, with per basic ADR dropping to US$9.42 due to share count increase.
Kazia Therapeutics Limited (NASDAQ: KZIA) has revealed promising interim data from its phase I clinical trial of paxalisib in combination with radiotherapy for treating brain metastases. Conducted by Memorial Sloan Kettering Cancer Center, the trial showed a remarkable overall response rate of 100% in evaluable patients, compared to typical rates of 20-45% with standard radiotherapy. The data will be presented at the 2022 Annual Conference on CNS Clinical Trials and Brain Metastases in Toronto. Recruitment for the expansion stage of the trial is underway, aiming for an additional 12 patients.
Kazia Therapeutics Limited (NASDAQ: KZIA) has launched a new Scientific Advisory Board (SAB) to guide the development of its brain cancer treatment, paxalisib. The SAB includes four renowned experts in brain cancer research: Dr. Priscilla Brastianos, Dr. John de Groot, Dr. Alan Olivero, and Dr. Patrick Wen. Their expertise is crucial as paxalisib approaches the completion of the GBM AGILE clinical trial, anticipated in the second half of 2023. Kazia's CEO, Dr. James Garner, acknowledged the contributions of previous SAB members and emphasized the importance of this new team's guidance for the drug's potential commercialization.
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA) announced that the FDA granted Rare Pediatric Disease Designation (RPDD) for its drug paxalisib, targeting atypical rhabdoid/teratoid tumors, a rare and aggressive childhood brain cancer. This designation may lead to a pediatric priority review voucher (pPRV), which can significantly shorten the FDA review process and has historically been valued over $100 million. The RPDD follows positive preclinical results presented at the AACR Annual Meeting in April 2022. Kazia is advancing clinical trials, including a phase II study of paxalisib.
Kazia Therapeutics Limited (NASDAQ: KZIA) has announced that the FDA has granted Orphan Drug Designation (ODD) for its drug, paxalisib, to treat atypical rhabdoid/teratoid tumors (AT/RT), a rare and aggressive childhood brain cancer. This designation provides advantages such as up to seven years of exclusivity and potential savings of over US$3 million in fees for regulatory filings. Paxalisib has previously received ODD for malignant glioma. The company continues its clinical studies to evaluate paxalisib’s efficacy in various brain cancers.